Effects of fermented Sorghum bicolor L. Moench extract on inflammation and thickness in a vascular cell and atherosclerotic mice model
- 93 Downloads
Atherosclerosis is a major cause of coronary heart disease. As a result of the development of atherosclerotic lesions, the walls of blood vessels become thicker and inhibit blood circulation. Atherosclerosis is caused by a high-fat diet and vascular injury. Chronic arterial inflammation plays an important role in the pathogenesis of atherosclerosis. In particular, secretion of the pro-atherogenic cytokine tumor necrosis factor-α induces expression of endothelial adhesion molecules including P-selectin, vascular cell adhesion molecule 1 (VCAM-1), and intercellular adhesion molecule 1 (ICAM-1), which mediate attachment of circulating monocytes and lymphocytes. In this study, we examined the anti-atherosclerotic effect of sorghum, which is known to have anti-oxidant and anti-inflammatory activity. A 50% ethanol extract of Sorghum bicolor L. Moench fermented with Aspergillus oryzae NK (fSBE) was used for experiments. In vitro expression of endothelial adhesion molecules VCAM-1 and ICAM-1 and pro-inflammatory factor cyclooxygenase-2 was significantly decreased and that of the anti-atherogenic factor heme oxygenase-1 significantly increased by fSBE (P < 0.05). At the in vivo level, we examined fat droplets of liver tissue, and aortic thickness via histological analysis, and determined the blood lipid profile through chemical analysis. fSBE at a dose of 200 mg/kg significantly improved blood and vascular health (P < 0.05). Taken together, these results demonstrate that fSBE has potential as a therapeutic anti-atherosclerotic agent.
KeywordsSorghum bicolor Aspergillus oryzae Fermentation Anti-inflammation Anti-atherogenic
This research was supported by the Ministry of Trade, Industry & Energy (MOTIE), Korea Institute for Advancement of Technology (KIAT) through the Encouragement Program for The Industries of Economic Cooperation Region (R0000429).
Compliance with ethical standards
Conflict of interest
The authors declare that they have no conflict of interest.
- 2.Nakagawa K, Nakashima Y (2018) Pathologic intimal thickening in human atherosclerosis is foamed by cellular accumulation of plasma-derived lipids and dispersion of intimal smooth muscle cells. Atherosclerosis. https://doi.org/10.1016/j.atherosclerosis.2018.03.039 Google Scholar
- 5.Schmitz B, Vischer P, Brand E, Schmidt-Petersen K, Korb-Pap A, Guske K, Nedele J, Schelleckes M, Hillen J, Rotrige A, Simmet T, Paul M, Cambien F, Brand SM (2013) Increased monocyte adhesion by endothelial expression of VCAM-1 missense variation in vitro. Atherosclerosis 230:185–190CrossRefGoogle Scholar
- 11.Vanamal JKP, Massey AR, Pinnamaneni SR, Reddivari L, Reardon KF (2017) Grain and sweet sorghum (Sorghum bicolor L. Moench) serves as a novel source of bioactive compounds for human health. Crit Rev Food Sci Nutr. https://doi.org/10.1080/10408398.2017.1344186
- 16.Soetank O, Oyekunle MA, Aiyelaagbe OO, Fafunso MA (2006) Evaluation of the antimicrobial activity of saponins extract of Sorghum bicolor L. Moench. Afr J Biotechnol 5:2405–2407Google Scholar
- 20.Hwang SJ, Ballantyne CM, Sharrett AR, Smith LC, Davis CE, Gotto AM Jr, Boerwinkle E (1997) Circulating adhesion molecules VCAM-1, ICAM-1 and E-selectin in carotid atherosclerosis and incident coronary heart disease cases: the Atherosclerosis Risk In Communities (ARIC) study. Circulation 96:4219–4225CrossRefGoogle Scholar
- 21.Jiang Y, Jiang LLI, Maimaitirexiati XMZY, Zhang Y, Wu L (2015) Irbesartan attenuates TNF-a-induced ICAM-1, VCAM-1, and E-selectin expression through suppression of NF-κB pathway in HUVECs. Eur Rev Med Pharmacol Sci 19:3295–3302Google Scholar
- 26.Badimon L, Storey RF, Vilahur G (2011) Updateon lipids, inflammation and atherothrombosis. Thromb Haemost 105(Suppl 1):S34–S42Google Scholar
- 28.Linz PE, Lovato LC, Byington RP, O’Connor PJ, Leiter LA, Weiss D, Force RW, Crouse JR, Ismail-Beigi F, Simmons DL, Papademetriou V, Ginsberg HN, Elam MB (2014) Paradoxical reduction in HDL-C with fenofibrate and thiazolidinedione therapy in type 2 diabetes: the ACCORD lipid trial. Diabetes Care 37:686–693CrossRefGoogle Scholar
- 35.Bumrungpert A, Lilitchan S, Tuntipopipat S, Tirawanchai N, Komindr S (2018) Ferulic acid supplementation improves lipid profiles, oxidative stress, and inflammatory status in hyperlipidemic subjects: a randomized, double-blind, placebo-controlled clinical trial. Nutrients 10:713–720CrossRefGoogle Scholar